Morgan Stanley downgraded MorphoSys to Equal Weight from Overweight with a price target of $10.40, up from $9.20. The analyst expects European Union biopharma to offer a “safe haven” from macro and earnings growth concerns. While the firm continues to favor growth and innovation narratives in biopharma over the long term, it expects investors to reward earnings upgrade stories near term.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MOR:
